Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

European Heart Journal

Volumn 36, Issue 9, 2015, Pages 566-575

  Santos, Raul D ^a   Duell, P Barton ^b   East, Cara ^c   Guyton, John R ^d   Moriarty, Patrick M ^e   Chin, Wai ^f   Mittleman, Robert S ^f  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF KANSAS   (United States)

^f GENZYME CORPORATION   (United States)

Author keywords

Adverse events; Familial hypercholesterolaemia; Hypercholesterolaemia; Lipid lowering; Long term safety

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; APOLIPOPROTEIN A1; HYPOCHOLESTEROLEMIC AGENT; OLIGONUCLEOTIDE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABNORMAL LABORATORY RESULT; APPENDICITIS; ARTICLE; BILIARY COLIC; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; EYE DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPATHOLOGY; INJECTION SITE REACTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; MENTAL DISEASE; METABOLIC DISORDER; MINIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; STEADY STATE; THORAX DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; HEART DISEASES; HYPERLIPOPROTEINEMIA TYPE II; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DRUG SUBSTITUTION; FEMALE; HEART DISEASES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; RISK ASSESSMENT; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84924415690     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht549     Document Type: Article

References (26)

1. Haddley K. Mipomersen sodium: a new option for the treatment of familial hypercholesterolemia. Drugs Today (Barc) 2011;47:891-901.
2. Bel DA, Hooper AJ, Burnett JR. Mipomersen, an antisense apolipoproteinBsynthesis inhibitor. Expert Opin Investig Drugs 2011;20:1-8.
3. Ricotta DN, Frishman W. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol Rev 2012;20:90-95.
4. Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UH, Nederveen AJ, Verheij J, Trip MD, Basart DC, Kastelein JJ, Stroes ES. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012;33:1142-1149.
5. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDLcholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomised, doubleblind, placebo-controlled trial. Lancet 2010;375:998-1006.
6. Stein EA, Dufor R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012;126:2283-2292.
7. McGowan M, Tardif JC, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, Wagener G, Chasan-Taber S. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE 2012;7:e49006.
8. Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, doubleblind, placebo-controlled trial. JACC 2013.
9. Yokoo T, Bydder M, Hamilton G, Middleton MS, Gamst AC, Wolfson T, Hassanein T, Patton HM, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-Angle multiecho gradient-recalled-echo MR imaging at 1.5T. Radiology 2009;251:67-76.
10. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing clinical evaluation. 2009. http://www.fdanews.com/ext/files/UCM174090.pdf (Accessed 5 September 2012).
11. Visser ME, Akdim F, Tribble DL, Nederveen AJ, Kwoh TJ, Kastelein JJ, Trip MD, Stroes ES. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patientswith familial hypercholesterolemia. J LipidRes 2010;51:1057-1062.
12. Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, Marais AD. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011;124:2202-2207.
13. Nemati MH, Astaneh B. Optimal management of familial hypercholesterolemia: treatment and management strategies. Vasc Health Risk Manag 2010;6:1079-1088.
14. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999;142:105-112.
15. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AM, Propert KJ, Sasiela WJ, Bloedon LT, Rader DJ. Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-Arm, open-label, phase 3 study. Lancet 2013;381:40-46.
16. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36.
17. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-Analysis of data from 170000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
18. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990;322:1494-1499.
19. Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 2012;60:716-721.
20. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps O, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Hansen AT. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-2853.
21. Merki E, Graham MJ, Mullick AE, Miller ER, Crooke RM, Pitas RE, Witztum JL, Tsimikas S. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008;118:743-753.
22. Tarugi P, Averna M. Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. Adv Clin Chem 2011;54:81-107.
23. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterol 1999;116:1413-1419.
24. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1006-1012.
25. Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008;14:285-292.
26. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Ostergaard M. All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.